Kyntra Bio (NASDAQ:KYNB) Shares Down 1.5% – Here’s Why

Posted by Geri Gentry on Jun 7th, 2026

Kyntra Bio Inc (NASDAQ:KYNB – Get Free Report)’s stock price dropped 1.5% on Friday . The stock traded as low as $6.65 and last traded at $6.71. Approximately 6,835 shares changed hands during trading, a decline of 17% from the average daily volume of 8,230 shares. The stock had previously closed at $6.81.

Wall Street Analyst Weigh In

KYNB has been the topic of several analyst reports. HC Wainwright raised shares of Kyntra Bio to a “strong-buy” rating in a report on Friday, February 27th. Wall Street Zen raised shares of Kyntra Bio from a “sell” rating to a “hold” rating in a report on Saturday, April 18th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold”.

Check Out Our Latest Analysis on Kyntra Bio

Kyntra Bio Stock Performance

The stock has a market capitalization of $27.18 million, a price-to-earnings ratio of 0.17 and a beta of 1.01. The business’s fifty day moving average is $7.00.

Hedge Funds Weigh In On Kyntra Bio

An institutional investor recently bought a new position in Kyntra Bio stock. ADAR1 Capital Management LLC acquired a new stake in shares of Kyntra Bio Inc (NASDAQ:KYNB – Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 10,469 shares of the company’s stock, valued at approximately $71,000. ADAR1 Capital Management LLC owned about 0.26% of Kyntra Bio at the end of the most recent reporting period. Institutional investors and hedge funds own 72.71% of the company’s stock.

Kyntra Bio Company Profile

(Get Free Report)

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.